Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Bicara Therapeutics (BCAX) to $45 from $42 and keeps a Buy rating on the shares after the company presented Phase 1/1b results from a Part B dose-expansion cohort evaluating ficerafusp alfa plus Keytruda in patients with locally advanced/unresectable or metastatic EGFR+ squamous cell carcinoma of the anal cancer. The firm says the data provide potential upside to its forecasts.